Employer-sponsored health plans in 2024 may resort again to passing costs on to their workers as medical inflation heats up, aided by demand for weight-loss drugs such as Wegovy, employee benefit advisers say.
Medical plan costs are forecast to rise 7% to 7.5%, and costs for outpatient prescription drugs are expected to go up 10%, according to the Segal Group Inc., a benefits consulting company.
The focus on rising costs comes as open enrollment starts in October for many employers. Employers in recent years have tried to avoid passing on cost increases to their workers to keep health costs more ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.